Feifan Yao
Overview
Explore the profile of Feifan Yao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang H, Xiao P, Yao F, Zhang Q, Gong Y
Sci Rep
. 2025 Feb;
15(1):4753.
PMID: 39922922
In view of the complex environments and varying object scales in drone-captured imagery, a novel PARE-YOLO algorithm based on YOLOv8 for small object detection is proposed. This model enhances feature...
2.
Zhang R, Dai J, Yao F, Zhou S, Huang W, Xu J, et al.
iScience
. 2024 May;
27(6):109821.
PMID: 38770131
The cyclic AMP-responsive element-binding protein (CREB)-regulated transcription coactivator 2 (CRTC2) is a crucial regulator of hepatic lipid metabolism and gluconeogenesis and correlates with tumorigenesis. However, the mechanism through which CRTC2...
3.
Yao F, Zhou S, Zhang R, Chen Y, Huang W, Yu K, et al.
Cancer Lett
. 2024 May;
593:216935.
PMID: 38704136
Hepatocellular carcinoma (HCC) is a prevalent malignancy characterized by complex heterogeneity and drug resistance. Resistance to ferroptosis is closely related to the progression of HCC. While HCC tumors vary in...
4.
Dai J, Zhang L, Zhang R, Ge J, Yao F, Zhou S, et al.
Cell Mol Gastroenterol Hepatol
. 2023 Nov;
17(3):399-421.
PMID: 38036082
Background & Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a common chronic liver disease worldwide. No effective pharmacologic therapies for MASH have been developed; to develop such promising drugs, the underlying...
5.
Zhang L, Xu J, Zhou S, Yao F, Zhang R, You W, et al.
J Hepatol
. 2023 Oct;
80(1):82-98.
PMID: 37838036
Background & Aims: Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide. The tumor microenvironment (TME) contributes to the poor response of patients with HCC to current...
6.
Li Q, Zhang L, Yang Q, Li M, Pan X, Xu J, et al.
Cell Metab
. 2023 Apr;
35(6):912-927.e7.
PMID: 37071992
Metabolic reprogramming plays a crucial role in the development of hepatocellular carcinoma (HCC). However, the key drivers of metabolic reprogramming underlying HCC progression remain unclear. Using a large-scale transcriptomic database...
7.
Li Q, Zhang L, You W, Xu J, Dai J, Hua D, et al.
Nat Commun
. 2022 Dec;
13(1):7677.
PMID: 36509766
Programmed death receptor-1 (PD-1) blockade have achieved some efficacy but only in a fraction of patients with hepatocellular carcinoma (HCC). Programmed cell death 1 ligand 1 (PD-L1) binds to its...
8.
Xu J, Zhang L, Li N, Dai J, Zhang R, Yao F, et al.
Cancer Lett
. 2022 Oct;
552:215970.
PMID: 36265652
Hepatocellular carcinoma (HCC) is a leading malignancy of the digestive system, especially in China. Although radiotherapy, chemotherapy, and transarterial chemoembolization have achieved tremendous success, surgical resection remains the primary treatment...
9.
Chen S, Yao F, Ren S, Yang J, Yang Q, Yuan S, et al.
Opt Express
. 2022 Oct;
30(14):24461-24480.
PMID: 36237001
For FPI sensor demodulation systems to be used in actual engineering measurement, they must have high performance, low cost, stability, and scalability. Excellent performance, however, necessitates expensive equipment and advanced...
10.
Chen S, Yao F, Ren S, Wang G, Huang M
Opt Express
. 2022 Mar;
30(5):7647-7663.
PMID: 35299522
Fiber Bragg grating (FBG) sensors have been widely applied in various applications, especially for structural health monitoring. Low cost, wide range, and low error are necessary for an excellent performance...